171 related articles for article (PubMed ID: 9666022)
1. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications.
McGinnis MR; Pasarell L
J Clin Microbiol; 1998 Aug; 36(8):2353-5. PubMed ID: 9666022
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of voriconazole against selected fungi.
McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG
Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
Johnson EM; Szekely A; Warnock DW
J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
[TBL] [Abstract][Full Text] [Related]
6. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
7. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
Arikan S; Lozano-Chiu M; Paetznick V; Nangia S; Rex JH
J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
Morace G; Drago M; Scaltrito MM; Conti S; Fanti F; Polonelli L;
J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
[TBL] [Abstract][Full Text] [Related]
9. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
[TBL] [Abstract][Full Text] [Related]
11. In vitro antifungal susceptibility and molecular identity of 99 clinical isolates of the opportunistic fungal genus Curvularia.
da Cunha KC; Sutton DA; Fothergill AW; Gené J; Cano J; Madrid H; Hoog Sd; Crous PW; Guarro J
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):168-74. PubMed ID: 23558007
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
Oakley KL; Moore CB; Denning DW
J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
[TBL] [Abstract][Full Text] [Related]
14. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B.
McGinnis MR; Nordoff N; Li RK; Pasarell L; Warnock DW
Med Mycol; 2001 Aug; 39(4):369-71. PubMed ID: 11556767
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
Najafzadeh MJ; Badali H; Illnait-Zaragozi MT; De Hoog GS; Meis JF
Antimicrob Agents Chemother; 2010 Apr; 54(4):1636-8. PubMed ID: 20086140
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.
Li RK; Ciblak MA; Nordoff N; Pasarell L; Warnock DW; McGinnis MR
Antimicrob Agents Chemother; 2000 Jun; 44(6):1734-6. PubMed ID: 10817743
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
